LOGIN  |  REGISTER
Astria Therapeutics

Universal Health Services Appoints Darren Lehrich as Vice President of Investor Relations

September 15, 2025 | Last Trade: US$220.28 5.02 -2.23

KING OF PRUSSIA, Pa., Sept. 15, 2025 /PRNewswire/ -- Universal Health Services, Inc. (NYSE: UHS), one of the largest and most respected providers of hospital and healthcare services, announced today that Darren Lehrich has joined as Vice President of Investor Relations. Lehrich reports to CFO Steve Filton in the newly established investor relations role.

Lehrich joins UHS from Help at Home where he served in strategic finance leadership roles since 2022 including Senior Vice President of investor relations and finance and most recently as CFO. He previously led investor relations for Magellan Health Inc. and American Renal Associates Holdings Inc.

Prior to his corporate finance leadership roles, Lehrich covered the healthcare industry for 17 years as an equity research analyst. He led Deutsche Bank's healthcare providers coverage as managing director from 2005-2015 and served in similar financial analyst roles at Piper Jaffray, SunTrust Robinson Humphrey and Furman Selz.

Lehrich holds a Bachelor's degree in Health Policy and Administration from Pennsylvania State University and an MBA in Finance from Purdue University.

"Darren is a well-regarded investor relations professional and strategic finance leader who brings strong, trusting relationships within the investor and analyst community," said Steve Filton, EVP and CFO, UHS. "Darren's coverage of the industry and UHS, coupled with his experience in building investor relations functions, make him an ideal partner for me and the UHS leadership team. We are excited to welcome Darren to the UHS team."

About Universal Health Services 

One of the nation's largest and most respected providers of hospital and healthcare services, Universal Health Services, Inc. has built an impressive record of achievement and performance. Growing steadily since our inception into an esteemed Fortune 300 corporation, our annual revenues during 2024 were approximately $15.8 billion. In 2025, UHS was again recognized as one of the World's Most Admired Companies by Fortune; ranked #271 on the Fortune 500; and in 2024, ranked #399 among U.S. companies on Forbes Global 2000 World's Largest Public Companies.

Our operating philosophy is as effective today as it was upon the Company's founding in 1979, enabling us to provide compassionate care to our patients and their loved ones. Our strategy includes building or acquiring high quality hospitals in rapidly growing markets, investing in the people and equipment needed to allow each facility to thrive, and becoming the leading healthcare provider in each community we serve.

Headquartered in King of Prussia, PA, UHS has approximately 99,000 employees and through its subsidiaries operates 29 inpatient acute care hospitals, 331 inpatient behavioral health facilities, 60 outpatient and other facilities, an insurance offering, a physician network and various related services located in 39 U.S. States, Washington, D.C., Puerto Rico and the United Kingdom. It acts as the advisor to Universal Health Realty Income Trust, a real estate investment trust (NYSE:UHT). For additional information visit www.uhs.com.

Recursion

Stock Quote

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page